Fig. 5
From: Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
Fine-tuned CAIX targeted G9-41BB CAR-T cells exhibited superior efficacy in a ccRCC orthotopic NSG-SGM3 mouse model. (A) CAR-T expansion (the percentage of human CD45 + immune cells out of total live leukocytes in the peripheral blood) of G9 (pink), G36 (orange), G250 (green) and A716 (grey) is shown in the plot (n = 5 per group). Peripheral blood was analyzed via flow cytometry. ccRCC skrc-59 tumor cells were inoculated under the kidney capsule. One week after tumor implantation, one million CAR-T cells were injected intravenously. Tumor growth was monitored by BLI weekly for four weeks and circulating CAR-T cells were phenotyped weekly by flow cytometric analysis of peripheral blood. (B) Tumor growth curve of the mice treated with one million CD4:CD8 = 2:1 G9 (pink), G36 (orange), G250 (green) or A716 (grey) CAR-T cells (n = 5 per group). BLI was performed on Day 0, Day 7, Day 14, Day 21 and Day 28 after CAR-T infusion. (C) BLI images of mice treated with one million CD4:CD8 = 2:1 G9 (pink), G36 (orange), G250 (green) or A716 (grey) CAR-T cells on Day 0, Day 7, Day 14, Day 21 and Day 28 after CAR-T infusion. The red arrow indicates the lung metastasis of RCC tumor. All data with error bars are presented as mean ± SD. P values are defined by unpaired two-tailed t-tests (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; and ∗∗∗∗p < 0.0001)